What Is In-Licensing?
Licensing deals might be pharma’s preferred mode of business development these days—perhaps even more so than outright acquisitions.
Your trusted source for investing success
Your trusted source for investing success
Chelsea holds a Master’s degree in English Literature from McGill University, where her research focused on early modern ideas of death. These days, she writes about just the opposite—life, and the industries that change our experience of it. As the Life Science Editor for Investing News Network, Chelsea covers developments in biotech, pharma, genetics, and medical devices.
When she’s not writing, you can find Chelsea running, practicing yoga, and reading everything from Shakespeare to Stephen King.
Licensing deals might be pharma’s preferred mode of business development these days—perhaps even more so than outright acquisitions.
Punnett squares and phenotypes, chromatids and codominance: genetics, and all of its associated terms, isn’t the easiest field to understand. And yet experts agree: this is the future of medicine.
Drugs with low oral bioavailability risk failure in clinical trial: minimal absorption, after all, can translate to reduced efficacy. As a result, pharmaceutical companies look for alternative drug delivery methods.
The US Patent Office has ruled “no interference in fact” on CRISPR-Cas9 Patent dispute.
Artificial intelligence is revolutionizing technology, but also medicine. Here’s how.
What exactly are mesenchymal stem cells … and more importantly, why should investors care?
Herceptin, Enbrel, Botox: at first glance, these therapies may appear to have little in common.
When generic competitors enter the market, sales from a blockbuster drug can decrease significantly.
From serums and masks to oral sprays and enriched waters, we’re counting down the novel ways in which some cannabis-based biotechs are entering this space.
The body already has amazing regenerative abilities—can we not harness that power and, in turn, amplify it?
These three blockbuster drugs transformed pharmaceutical investing. But will we ever see anything like them again?
Precision medicine, medtech, “going beyond the pill”: these common phrases are signposts, marking the future path of medicine. Here’s another you should know: collaborative care.
You’ve heard it before … but this time, it really does look like the gene therapy revolution is drawing near.
Deep breaths, biotech investors. 2016 was a rough one—but the year ahead looks bright.
Through the rise of bioelectronics and medtech, medical device manufacturers are claiming major market share.
No doubt about it—2016 was a tumultuous year for biotech. But that doesn’t mean you should be afraid of this sector.
Pharma stocks are far from a sure thing, but with the following insight from our industry experts, you’ll be better positioned to foresee at least some of the market’s peaks and plummets.
What can you expect from genetics stocks in 2017? We touched base with those in the know to bring you some predictions for the year ahead.
From precision meds to the ongoing CRISPR-Cas9 saga, here are the top genetics news stories of 2016. We expect each to have major ripple effects in 2017 and beyond.
From cybersecurity to bioelectronics, medical device topics are garnering increased media coverage.
Send this to a friend
